Literature DB >> 20304022

Auditory and visual P300 reflecting cognitive improvement in patients with schizophrenia with quetiapine: a pilot study.

E-Jin Park1, Sang-Ick Han, Yang-Whan Jeon.   

Abstract

We recorded event-related potentials (ERPs) in patients with schizophrenia before and after treatment with quetiapine, to investigate this drug's effects on cognitive function. Auditory and visual oddball stimulus discrimination paradigms were presented to patients with schizophrenia (N=20) before and after 3months' treatment with quetiapine. The 2-stimulus auditory oddball paradigm used a standard tone (1000Hz, 75dB, 80%) and a target tone (2000Hz, 75dB, 20%). The 2-stimulus visual oddball paradigm used a standard stimulus (small circle, 80%) and a target stimulus (large circle, 20%). Patients' severity of psychopathology was initially evaluated with the Positive and Negative Syndrome Scale (PANSS) and was likewise re-evaluated after treatment. After treatment with quetiapine, patients' P300 amplitudes increased over baseline for both tasks (auditory stimuli, P<0.01; visual stimuli, P<0.01) and their P300 latencies for both target stimuli decreased significantly (auditory stimuli, P<0.001; visual stimuli, P<0.01). Visual P300 amplitude was negatively correlated with the severity of positive symptoms at the Fz electrode before the treatment (r=-0.45, P<0.05). After treatment with quetiapine, there were no significant correlations between severity of positive or negative symptoms and visual P300 amplitudes for midline electrodes. These findings suggest that the reduced and delayed P300 may be a state marker for schizophrenia, which may in turn be modulated by positive symptoms, and also suggest that the amplitude and latency for both auditory and visual tasks may be decreased by quetiapine treatment. Based on these results, we suggest that the atypical antipsychotic quetiapine may improve some aspects of cognitive domains in patients with schizophrenia. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20304022     DOI: 10.1016/j.pnpbp.2010.03.011

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  4 in total

1.  Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing-study on P300 and mismatch negativity in healthy volunteers.

Authors:  Anna Bravermanová; Michaela Viktorinová; Filip Tylš; Tomáš Novák; Renáta Androvičová; Jakub Korčák; Jiří Horáček; Marie Balíková; Inga Griškova-Bulanova; Dominika Danielová; Přemysl Vlček; Pavel Mohr; Martin Brunovský; Vlastimil Koudelka; Tomáš Páleníček
Journal:  Psychopharmacology (Berl)       Date:  2018-01-05       Impact factor: 4.530

2.  Event-related potentials to rare visual targets and negative symptom severity in a transdiagnostic psychiatric sample.

Authors:  Giulia C Salgari; Geoffrey F Potts; Joseph Schmidt; Chi C Chan; Christopher C Spencer; Jeffrey S Bedwell
Journal:  Clin Neurophysiol       Date:  2021-04-09       Impact factor: 4.861

3.  Effects of differences in serum total homocysteine, folate, and vitamin B12 on cognitive impairment in stroke patients.

Authors:  Bo Jiang; Yumei Chen; Guoen Yao; Cunshan Yao; Hongmei Zhao; Xiangdong Jia; Yunyan Zhang; Junling Ge; Enchao Qiu; Chengyun Ding
Journal:  BMC Neurol       Date:  2014-11-30       Impact factor: 2.474

4.  P300 aberration in first-episode schizophrenia patients: a meta-analysis.

Authors:  Yao-qin Qiu; Yun-xiang Tang; Raymond C K Chan; Xin-yang Sun; Jia He
Journal:  PLoS One       Date:  2014-06-16       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.